PerkinElmer (NY: PKI )
Press releases about PerkinElmer
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA)...
OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to...
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%,...
PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer, Inc. (NYSE: PKI) ("PerkinElmer") and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the "Company") are pleased to announce they have reached an agreement on terms under...
PerkinElmer to Present at J.P. Morgan Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Monday,...
PerkinElmer to Host Virtual Life Science Event
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a Virtual Life Science Event for the investment community on...
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five...
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA...
PerkinElmer to Present at Wolfe Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday,...
PerkinElmer to Present at Stifel Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday,...
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million).
PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus...
PerkinElmer Announces Financial Results for the Third Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020.
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries...
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to all...
PerkinElmer Immunoassay Helps NIH NCATS Team Identify Therapeutic Compounds Capable of Disrupting the SARS-CoV-2 Spike Protein/ACE2 Interaction
Covid-19 News: The NIH's NCATS division is using PerkinElmer's AlphaLISA immunoassay to screen compounds for potential drug repurposing candidates.
High Content Screening Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025
From AB Newswire
CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020
The table in the release was incorrect. The corrected table should read:
PerkinElmer to Present at BofA Global Healthcare Conference 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Global Healthcare Conference 2020 on Wednesday,...
PerkinElmer to Present at Baird's 2020 Virtual Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at Baird's 2020 Virtual Global Healthcare Conference on...
PerkinElmer Enhances Hand Sanitizer Analyzer to Detect Methanol in 30 Seconds or Less
PerkinElmer announces its Hand Sanitizer Analyzer instrument tests for the presence of methanol with pass/fail results delivered in 30 seconds.
PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a series of explorer™ workstations for SARS-CoV-2 testing capable of preparing...
PerkinElmer Announces Financial Results for the Second Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 5, 2020.
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock July 23, 2020. This dividend is payable on November 6, 2020 to all...
PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA®...
PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately...
PerkinElmer and American Society of Hematology Announce Global Collaboration to Help Combat Sickle Cell Disease
Initiative to enhance newborn screening in underserved populations for improved health outcomes in Africa
From PR Newswire
PerkinElmer to Present at Jefferies Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on...
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into...
PerkinElmer Announces Financial Results for the First Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 5, 2020.